MedWellAI, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that MedWellAI, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $594.8K | Sep 30, 2025 |
| FY2025 | Jun 30, 2024 | $0 | Sep 30, 2025 |
| FY2024 | Jun 30, 2023 | $3.86M | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $6.55M | May 10, 2024 |
| FY2021 | Sep 30, 2021 | $1.92M | Nov 15, 2021 |
| FY2022 | Jun 30, 2021 | $1.85M | Sep 28, 2022 |
| FY2021 | Sep 30, 2020 | $83.2K | Nov 15, 2021 |
| FY2021 | Jun 30, 2020 | $454.2K | Sep 24, 2021 |
| FY2020 | Jun 30, 2019 | $279.1K | Sep 23, 2020 |
| FY2019 | Jun 30, 2018 | $306.4K | Sep 30, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Jun 30, 2023 | ($2.43M) | May 10, 2024 |
| FY2023 | Jun 30, 2022 | $2.68M | May 10, 2024 |
| FY2021 | Sep 30, 2021 | $842.1K | Nov 15, 2021 |
| FY2022 | Jun 30, 2021 | $931.0K | Sep 28, 2022 |
| FY2021 | Sep 30, 2020 | ($106.8K) | Nov 15, 2021 |
| FY2021 | Jun 30, 2020 | ($542.2K) | Sep 24, 2021 |
| FY2020 | Jun 30, 2019 | ($726.3K) | Sep 23, 2020 |
| FY2019 | Jun 30, 2018 | $68.6K | Sep 30, 2019 |
| FY2015 | Dec 31, 2014 | $93.8K | Jul 24, 2015 |
| FY2015 | Dec 31, 2013 | $107.1K | Jul 24, 2015 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($3.61M) | Sep 30, 2025 |
| FY2025 | Jun 30, 2024 | ($11.52M) | Sep 30, 2025 |
| FY2024 | Jun 30, 2023 | ($25.46M) | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | ($565.5K) | May 10, 2024 |
| FY2021 | Sep 30, 2021 | $1.35M | Nov 15, 2021 |
| FY2022 | Jun 30, 2021 | ($22.43M) | Sep 28, 2022 |
| FY2021 | Sep 30, 2020 | ($388.8K) | Nov 15, 2021 |
| FY2021 | Jun 30, 2020 | ($1.08M) | Sep 24, 2021 |
| FY2020 | Jun 30, 2019 | ($9.51M) | Sep 23, 2020 |
| FY2019 | Jun 30, 2018 | ($5.58M) | Sep 30, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($2.84M) | Sep 30, 2025 |
| FY2025 | Jun 30, 2024 | ($9.07M) | Sep 30, 2025 |
| FY2024 | Jun 30, 2023 | ($25.17M) | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | ($688.0K) | May 10, 2024 |
| FY2021 | Sep 30, 2021 | $630.8K | Nov 15, 2021 |
| FY2022 | Jun 30, 2021 | ($21.67M) | Sep 28, 2022 |
| FY2021 | Sep 30, 2020 | ($206.5K) | Nov 15, 2021 |
| FY2021 | Jun 30, 2020 | ($1.01M) | Sep 24, 2021 |
| FY2020 | Jun 30, 2019 | ($4.65M) | Sep 23, 2020 |
| FY2019 | Jun 30, 2018 | ($6.14M) | Sep 30, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Jun 30, 2017 | $21.6K | Dec 27, 2018 |
| FY2017 | Jun 30, 2016 | $120.2K | Sep 14, 2017 |
| FY2016 | Jun 30, 2015 | $10.3K | Sep 27, 2016 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Mar 31, 2014 | $30 | Jul 2, 2014 |
| FY2014 | Mar 31, 2013 | $30 | Jul 2, 2014 |
| FY2012 | Mar 31, 2012 | $83 | Jun 26, 2013 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($848.5K) | Sep 30, 2025 |
| FY2025 | Jun 30, 2024 | ($4.13M) | Sep 30, 2025 |
| FY2024 | Jun 30, 2023 | ($3.43M) | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $55.5K | May 10, 2024 |
| FY2021 | Sep 30, 2021 | $341 | Nov 15, 2021 |
| FY2022 | Jun 30, 2021 | ($1.57M) | Sep 28, 2022 |
| FY2021 | Sep 30, 2020 | ($210.4K) | Nov 15, 2021 |
| FY2021 | Jun 30, 2020 | ($671.1K) | Sep 24, 2021 |
| FY2020 | Jun 30, 2019 | ($708.0K) | Sep 23, 2020 |
| FY2019 | Jun 30, 2018 | ($1.15M) | Sep 30, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $2.2K | Sep 30, 2025 |
| FY2025 | Jun 30, 2024 | $0 | Sep 30, 2025 |
| FY2024 | Jun 30, 2023 | $0 | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $73.6K | May 10, 2024 |
| FY2021 | Sep 30, 2021 | $0 | Nov 15, 2021 |
| FY2022 | Jun 30, 2021 | $3.29M | Sep 28, 2022 |
| FY2021 | Sep 30, 2020 | $209.6K | Nov 15, 2021 |
| FY2021 | Jun 30, 2020 | $123.3K | Sep 24, 2021 |
| FY2020 | Jun 30, 2019 | ($42.4K) | Sep 23, 2020 |
| FY2019 | Jun 30, 2018 | ($612.4K) | Sep 30, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $805.5K | Sep 30, 2025 |
| FY2025 | Jun 30, 2024 | $3.94M | Sep 30, 2025 |
| FY2024 | Jun 30, 2023 | $6.59M | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $16.28M | May 10, 2024 |
| FY2021 | Sep 30, 2021 | $14.72M | Nov 15, 2021 |
| FY2022 | Jun 30, 2021 | $13.36M | Sep 28, 2022 |
| FY2021 | Jun 30, 2020 | $546.8K | Sep 24, 2021 |
| FY2020 | Jun 30, 2019 | $1.12M | Sep 23, 2020 |
| FY2019 | Jun 30, 2018 | $829.5K | Sep 30, 2019 |
| FY2018 | Jun 30, 2017 | $296.3K | Dec 27, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $3.14M | Sep 30, 2025 |
| FY2025 | Jun 30, 2024 | $3.68M | Sep 30, 2025 |
| FY2021 | Sep 30, 2021 | $413.9K | Nov 15, 2021 |
| FY2021 | Jun 30, 2021 | $274.1K | Nov 15, 2021 |
| FY2021 | Jun 30, 2020 | $656.4K | Sep 24, 2021 |
| FY2020 | Jun 30, 2019 | $2.21M | Sep 23, 2020 |
| FY2019 | Jun 30, 2018 | $2.96M | Sep 30, 2019 |
| FY2018 | Jun 30, 2017 | $346.3K | Dec 27, 2018 |
| FY2017 | Jun 30, 2016 | $1.49M | Sep 14, 2017 |
| FY2016 | Jun 30, 2015 | $180.8K | Sep 27, 2016 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($6.62M) | Sep 30, 2025 |
| FY2025 | Jun 30, 2024 | ($3.87M) | Sep 30, 2025 |
| FY2024 | Jun 30, 2023 | ($509.9K) | Sep 30, 2024 |
| FY2024 | Jun 30, 2022 | $10.59M | Sep 30, 2024 |
| FY2021 | Sep 30, 2021 | $10.18M | Nov 15, 2021 |
| FY2023 | Jun 30, 2021 | $8.96M | May 10, 2024 |
| FY2021 | Sep 30, 2020 | ($252.2K) | Nov 15, 2021 |
| FY2022 | Jun 30, 2020 | ($109.6K) | Sep 28, 2022 |
| FY2021 | Jun 30, 2019 | ($1.09M) | Sep 24, 2021 |
| FY2020 | Jun 30, 2018 | ($2.13M) | Sep 23, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Jun 30, 2018 | $4.15M | Dec 27, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($88.67M) | Sep 30, 2025 |
| FY2025 | Jun 30, 2024 | ($85.07M) | Sep 30, 2025 |
| FY2024 | Jun 30, 2023 | ($73.10M) | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | ($46.19M) | May 10, 2024 |
| FY2021 | Sep 30, 2021 | ($43.86M) | Nov 15, 2021 |
| FY2022 | Jun 30, 2021 | ($45.08M) | Sep 28, 2022 |
| FY2021 | Jun 30, 2020 | ($22.06M) | Sep 24, 2021 |
| FY2020 | Jun 30, 2019 | ($20.98M) | Sep 23, 2020 |
| FY2019 | Jun 30, 2018 | ($11.47M) | Sep 30, 2019 |
| FY2018 | Jun 30, 2017 | ($5.89M) | Dec 27, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Jun 30, 2024 | $57.8K | Sep 30, 2024 |
| FY2024 | Jun 30, 2023 | $258.0K | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $490.3K | May 10, 2024 |
| FY2021 | Sep 30, 2021 | $687.3K | Nov 15, 2021 |
| FY2022 | Jun 30, 2021 | $2.10M | Sep 28, 2022 |
| FY2021 | Sep 30, 2020 | $102.4K | Nov 15, 2021 |
| FY2022 | Jun 30, 2020 | $6.7K | Sep 28, 2022 |
| FY2021 | Jun 30, 2019 | $48.3K | Sep 24, 2021 |
| FY2019 | Jun 30, 2018 | $41.1K | Sep 30, 2019 |
| FY2019 | Jun 30, 2017 | $15.7K | Sep 30, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Jun 30, 2024 | (2) | Sep 30, 2024 |
| FY2024 | Jun 30, 2023 | (11) | Sep 30, 2024 |
| FY2022 | Jun 30, 2022 | 0 | Sep 28, 2022 |
| FY2021 | Sep 30, 2021 | 0 | Nov 15, 2021 |
| FY2022 | Jun 30, 2021 | 0 | Sep 28, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Nov 15, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Jun 30, 2024 | (2) | Sep 30, 2024 |
| FY2024 | Jun 30, 2023 | (11) | Sep 30, 2024 |
| FY2021 | Sep 30, 2021 | 0 | Nov 15, 2021 |
| FY2021 | Sep 30, 2020 | 0 | Nov 15, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 6.19M | Sep 30, 2025 |
| FY2025 | Jun 30, 2024 | 5.06M | Sep 30, 2025 |
| FY2024 | Jun 30, 2023 | 2.86M | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | 1.66M | May 10, 2024 |
| FY2021 | Sep 30, 2021 | 204.96M | Nov 15, 2021 |
| FY2022 | Jun 30, 2021 | 194.49M | Sep 28, 2022 |
| FY2021 | Jun 30, 2020 | 103.16M | Sep 24, 2021 |
| FY2020 | Jun 30, 2019 | 29.82M | Sep 23, 2020 |
| FY2022 | Jan 25, 2019 | 194.49M | Sep 28, 2022 |
| FY2019 | Jun 30, 2018 | 8.96M | Sep 30, 2019 |